BACKGROUND: The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess lebrikizumab's effect on eosinophilic inflammation and remodelling. OBJECTIVE: To report safety and efficacy results from enrolled participants with available data from CLAVIER. METHODS: We performed bronchoscopy on patients with uncontrolled asthma before and after 12 weeks of randomized double-blinded treatment with lebrikizumab (n = 31) or placebo (n = 33). The pre-specified primary end-point was relative change in airway subepithelial eosinophils per mm2 of basement membrane (cells/mm2 ). Pre-specified secondary and exploratory outcomes included change in IL-13-associated biomarkers and measures of airway remodelling. RESULTS: There was a baseline imbalance in tissue eosinophils and high variability between treatment groups. There was no discernible change in adjusted mean subepithelial eosinophils/mm2 in response to lebrikizumab (95% CI, -82.5%, 97.5%). As previously observed, FEV1 increased after lebrikizumab treatment. Moreover, subepithelial collagen thickness decreased 21.5% after lebrikizumab treatment (95% CI, -32.9%, -10.2%), and fractional exhaled nitric oxide, CCL26 and SERPINB2 mRNA expression in bronchial tissues also reduced. Lebrikizumab was well tolerated, with a safety profile consistent with other lebrikizumab asthma studies. CONCLUSIONS & CLINICAL RELEVANCE: We did not observe reduced tissue eosinophil numbers in association with lebrikizumab treatment. However, in pre-specified exploratory analyses, lebrikizumab treatment was associated with reduced degree of subepithelial fibrosis, a feature of airway remodelling, as well as improved lung function and reduced key pharmacodynamic biomarkers in bronchial tissues. These results reinforce the importance of IL-13 in airway pathobiology and suggest that neutralization of IL-13 may reduce asthmatic airway remodelling. CLINICAL TRIAL REGISTRATION: NCT02099656.
RCT Entities:
BACKGROUND: The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess lebrikizumab's effect on eosinophilic inflammation and remodelling. OBJECTIVE: To report safety and efficacy results from enrolled participants with available data from CLAVIER. METHODS: We performed bronchoscopy on patients with uncontrolled asthma before and after 12 weeks of randomized double-blinded treatment with lebrikizumab (n = 31) or placebo (n = 33). The pre-specified primary end-point was relative change in airway subepithelial eosinophils per mm2 of basement membrane (cells/mm2 ). Pre-specified secondary and exploratory outcomes included change in IL-13-associated biomarkers and measures of airway remodelling. RESULTS: There was a baseline imbalance in tissue eosinophils and high variability between treatment groups. There was no discernible change in adjusted mean subepithelial eosinophils/mm2 in response to lebrikizumab (95% CI, -82.5%, 97.5%). As previously observed, FEV1 increased after lebrikizumab treatment. Moreover, subepithelial collagen thickness decreased 21.5% after lebrikizumab treatment (95% CI, -32.9%, -10.2%), and fractional exhaled nitric oxide, CCL26 and SERPINB2 mRNA expression in bronchial tissues also reduced. Lebrikizumab was well tolerated, with a safety profile consistent with other lebrikizumab asthma studies. CONCLUSIONS & CLINICAL RELEVANCE: We did not observe reduced tissue eosinophil numbers in association with lebrikizumab treatment. However, in pre-specified exploratory analyses, lebrikizumab treatment was associated with reduced degree of subepithelial fibrosis, a feature of airway remodelling, as well as improved lung function and reduced key pharmacodynamic biomarkers in bronchial tissues. These results reinforce the importance of IL-13 in airway pathobiology and suggest that neutralization of IL-13 may reduce asthmatic airway remodelling. CLINICAL TRIAL REGISTRATION: NCT02099656.
Authors: Catherine Lemière; Pierre Ernst; Ron Olivenstein; Yasuhiro Yamauchi; Karuthapillai Govindaraju; Mara S Ludwig; James G Martin; Qutayba Hamid Journal: J Allergy Clin Immunol Date: 2006-09-25 Impact factor: 10.793
Authors: Sharmilee M Nyenhuis; Jerry A Krishnan; Alalia Berry; William J Calhoun; Vernon M Chinchilli; Linda Engle; Nicole Grossman; Fernando Holguin; Elliot Israel; Rick A Kittles; Monica Kraft; Stephen C Lazarus; Erik B Lehman; David T Mauger; James N Moy; Stephen P Peters; Wanda Phipatanakul; Lewis J Smith; Kaharu Sumino; Stanley J Szefler; Michael E Wechsler; Sally Wenzel; Steven R White; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2017-01-06 Impact factor: 10.793
Authors: D Olivieri; A Chetta; M Del Donno; G Bertorelli; A Casalini; A Pesci; R Testi; A Foresi Journal: Am J Respir Crit Care Med Date: 1997-06 Impact factor: 21.405
Authors: S Horie; Y Okubo; M Hossain; E Sato; H Nomura; S Koyama; J Suzuki; M Isobe; M Sekiguchi Journal: Intern Med Date: 1997-03 Impact factor: 1.271
Authors: Sergei I Ochkur; John Dongil Kim; Cheryl A Protheroe; Dana Colbert; Rachel M Condjella; Sophie Bersoux; Richard A Helmers; Redwan Moqbel; Paige Lacy; Elizabeth A Kelly; Nizar N Jarjour; Robert Kern; Anju Peters; Robert P Schleimer; Glenn T Furuta; Parameswaran Nair; James J Lee; Nancy A Lee Journal: J Immunol Methods Date: 2012-06-28 Impact factor: 2.303
Authors: Guiquan Jia; Richard W Erickson; David F Choy; Sofia Mosesova; Lawren C Wu; Owen D Solberg; Aarti Shikotra; Richard Carter; Séverine Audusseau; Qutayba Hamid; Peter Bradding; John V Fahy; Prescott G Woodruff; Jeffrey M Harris; Joseph R Arron Journal: J Allergy Clin Immunol Date: 2012-08-01 Impact factor: 10.793
Authors: Andrew Gallagher; Michaela Edwards; Parameswaran Nair; Stewart Drew; Aashish Vyas; Rashmi Sharma; Paul A Marsden; Ran Wang; David Jw Evans Journal: Cochrane Database Syst Rev Date: 2021-10-19
Authors: Cary D Austin; Melissa Gonzalez Edick; Ronald E Ferrando; Margaret Solon; Miriam Baca; Kathryn Mesh; Peter Bradding; Gail M Gauvreau; Kaharu Sumino; J Mark FitzGerald; Elliot Israel; Lief Bjermer; Arnaud Bourdin; Joseph R Arron; David F Choy; Julie K Olsson; Francis Abreu; Monet Howard; Kit Wong; Fang Cai; Kun Peng; Wendy S Putnam; Cécile T J Holweg; John G Matthews; Monica Kraft; Prescott G Woodruff Journal: Clin Exp Allergy Date: 2020-10-04 Impact factor: 5.018